1Hirschfield GM,Pepys MB. C-reactive protein and cardiovascular dis-ease:new insights from an old molecule[J].{H}QUARTERLY JOURNAL OF MEDICINE,2003.793-807.
2Schieffer B,Schieffer E,Hilfiker-Kleiner D. Expression of angioten-sin II and interleukin 6 in human coronary atherosclerotic plaques:poten-tial implications for inflammation and plaque instability[J].{H}CIRCULATION,2000.1372-1378.
3Morrow DA,de Lemos JA,Sabatine MS. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syn-dromes in the Aggrastat-to-Zocor Trial[J].{H}CIRCULATION,2006.281-288.
4Cannon CP,McCabe CH,Belder R. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 tri-al[J].{H}American Journal of Cardiology,2002.860-861.
9Persson J, Nilsson J, Lindholm MW. Interleukin - 1 beta and tumour necrosis factor alpha impede neutral lipid turn over in macrophage derived foam cells [J]. BMC Immunology,2008,9: 70.
10Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Manage- ment of Patients with Unstable Angina) [J]. J Am Coll Cardiol, 2000, 36 (3). 970-1062.
